GleamWall
中文EN

PPCB Propanc Biopharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1517681 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY64.3%
TTM EPS YoY115.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-211.0%
ROA-159.8%
ROIC (approx.)-168.8%
Asset turnover—

Leverage & solvency

Liabilities / assets31.5%
Debt / equity0.00x
Current ratio2.47x
Interest coverage-154.29x

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-119.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q12026-09-302026Q4*2026-06-302026Q32026-03-312026Q22025-12-312026Q12025-09-302025Q4*2025-06-302025Q32025-03-312025Q22024-12-31
Income statement
Revenue————————
R&D expense$457,677$375,655$169,660$19,961$60,201$53,522$54,097$54,388
SG&A expense$182,728-$13.78M$6.22M$3.63M$137,341$3.59M$53.07M$153,593
Operating income-$8.57M-$3.46M-$6.40M-$3.65M-$4.67M-$3.65M-$53.13M-$213,382
Interest expense$18,244$27,665$38,270$58,955$305,649$254,542$104,042$118,943
Pretax income-$8.59M-$4.57M-$6.36M-$3.09M-$4.84M-$4.07M-$54.07M-$430,183
Net income-$8.59M-$4.57M-$6.36M-$3.09M-$4.84M-$4.07M-$54.07M-$430,183
EBITDA-$8.57M-$3.46M-$6.40M-$3.65M-$4.67M—-$53.13M—
EPS (basic)-12.22—-0.28-0.30-98.08—-12.50-32.23
EPS (diluted)-12.22—-0.28-0.30-98.08—-12.50-32.23
Weighted avg. shares (diluted)702,966—22.43M13.36M49,326—4.33M13,347
Balance sheet
Cash & equivalents$258,366$832,006$443,702$561,237$602,737$12,088$50,760$14,633
Current assets$8.00M$8.54M$8.22M$7.71M$8.76M$8.35M$9.74M$17,984
PP&E, net$4,030$3,915$4,221$4,397$2,364———
Total assets$10.33M$12.78M$14.33M$15.11M$17.98M$19.63M$22.53M$78,533
Current liabilities$3.24M$3.35M$3.48M$3.62M$3.57M$5.58M$4.34M$4.15M
Long-term debt——$55,000$55,000$106,968$537,921$438,578$409,799
Total debt——$55,000$55,000$106,968$537,921$438,578$409,799
Total liabilities$3.26M$3.38M$3.51M$3.66M$3.61M$5.73M$4.44M$4.24M
Shareholders' equity$7.07M$9.40M$9.83M$10.45M$14.36M$13.91M$18.09M-$4.16M
Net debt——-$388,702-$506,237-$495,769$525,833$387,818$395,166
Shares outstanding983,260331,08321.86M13.45M12.81M464,47111.61M14,508
Cash flow statement
Operating cash flow-$1.97M-$1.60M-$1.14M-$999,140-$1.94M-$27,186-$96,196-$6,271
Capital expenditure—$21$154$2,267$2,491———
Free cash flow—-$1.60M-$1.14M-$1.00M-$1.94M———
Investing cash flow—-$21-$154-$2,267-$2,491———
Financing cash flow$1.40M$1.98M$981,614$965,099$2.53M$7,756$147,485$79,816
Depreciation & amortization$354$327$316$229$125—$0—
Stock-based compensation$1.93M$1.23M$5.35M$1.79M$3.02M$3.12M$52.84M—

Free plan shows the latest 8 periods; Pro shows all 64 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.